Af­fimed spurs promis­ing re­sponse num­bers in NK cell study, but dura­bil­i­ty will be the big ques­tion

Ger­man biotech Af­fimed caught some at­ten­tion ear­li­er this year with a pair of com­plete re­spons­es in an ear­ly study of its NK cell reg­i­men for lym­phoma. The biotech is back with more da­ta from that study, and the re­sults look promis­ing — but will dura­bil­i­ty hold up?

A com­bi­na­tion reg­i­men of donor NK cells and Af­fimed’s CD30-tar­get­ing in­nate cell en­gager AFM13 spurred re­spons­es in 16 of 18 pa­tients with re­lapsed or re­frac­to­ry Hodgkin and non-Hodgkin lym­phomas, in­clud­ing sev­en com­plete re­spons­es, as part of the first of two rounds of treat­ment in a Phase I/II study, the biotech said Mon­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER